• This is a political forum that is non-biased/non-partisan and treats every person's position on topics equally. This debate forum is not aligned to any political party. In today's politics, many ideas are split between and even within all the political parties. Often we find ourselves agreeing on one platform but some topics break our mold. We are here to discuss them in a civil political debate. If this is your first visit to our political forums, be sure to check out the RULES. Registering for debate politics is necessary before posting. Register today to participate - it's free!

The next superbug threat is already here (1 Viewer)

Allan

Allan

DP Veteran
Joined
Sep 30, 2019
Messages
47,736
Reaction score
69,698
Gender
Male
Political Leaning
Liberal
Well it's a relief to finally know what's going to kill us all.

CNN — A new superbug threat is spreading around the world. The culprit: microscopic fungal spores that live in and on human bodies and in the dirt and air.

Fungi that maim and kill people are quickly spreading in the world today. Recent global estimates indicate there are 6.5 million invasive fungal infections and some 3.8 million deaths annually — and some of those infections are becoming more difficult to treat.

While deaths associated with bacterial superbugs are higher than those linked with fungi, (4.7 million vs. 3.8 million), there are hundreds of antibiotics available to treat bacteria. In contrast, only about 17 antifungal drugs are in use, according to the US Centers of Disease Control and Prevention. One reason why is the difficulty of making drugs that kill the fungus without hurting humans.
Click to expand...

 
Allan said:
Well it's a relief to finally know what's going to kill us all.



Click to expand...
www.who.int

WHO issues its first-ever reports on tests and treatments for fungal infections

WHO's reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, shows urgent need for innovative research and development (R&D) to close the gaps. Fungal diseases are an increasing public health concern, with common infections growing increasingly...
www.who.int www.who.int

April 1, 2025

The World Health Organization (WHO) today published its first-ever reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, showing the urgent need for innovative research and development (R&D) to close these gaps.

Fungal diseases are an increasing public health concern, with common infections – such as candida, which causes oral and vaginal thrush – growing increasingly resistant to treatment. These infections disproportionately impact severely ill patients and those with weakened immune systems, including individuals undergoing cancer chemotherapy, living with HIV, and who have had organ transplants.

“Invasive fungal infections threaten the lives of the most vulnerable but countries lack the treatments needed to save lives,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Antimicrobial Resistance ad interim. “Not only is the pipeline of new antifungal drugs and diagnostics insufficient, there is a void in fungal testing in low- and middle-income countries, even in district hospitals. This diagnostic gap means the cause of people’s suffering remains unknown, making it difficult to get them the right treatments.”

The fungi in the top ‘critical priority’ category of the WHO’s fungal priority pathogens list (FPPL) are deadly, with mortality rates reaching as high as 88%. Advancements in treatments mean that more people are likely to be living with immunocompromised conditions, which also could mean increases in cases of invasive fungal diseases. This is a complex challenge to manage due to inaccessibility of diagnostic tools, limited availability of antifungal medicines, and a slow and complex R&D process for new treatments.

Constrained process in developing treatments against deadly fungal infections

WHO’s report on antifungal drugs highlights that, in the past decade, only four new antifungal drugs have been approved by regulatory authorities in the United States of America, the European Union or China. Currently, nine antifungal medicines are in clinical development to use against the most health-threatening fungi, as detailed in the FPPL.

However, only three candidates are in phase 3, the final stage of clinical development, meaning few approvals are expected within the next decade. Twenty-two drugs are in preclinical development, an insufficient number to feed a clinical pipeline considering the dropout rates, risks and challenges associated with earlier development stages.

Issues with current antifungal treatments include serious side effects, frequent drug-drug interactions, limited dosage forms and the need for prolonged hospital stays. The report highlights the urgent need for safer antifungal medicines, possibly reducing requirements for continuous drug monitoring....
 
Where are the righties to tell us that everything is fine and they know more than the WHO? Have they succumbed to RFK, Jr.'s brain worm already?
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 2 (members: 0, guests: 2)
Back
Top Bottom